BioInvent International AB (BINV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioInvent International AB (BINV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10131
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioInvent International AB (BioInvent) focuses on the discovery and development of antibody drugs for the treatment of cancer. The company uses n-CoDeR, its inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company’s pipeline portfolio comprises THR-317, an antibody to treat patients with diabetic macular edema; BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and TB-403 being developed for the treatment of medulloblastoma. The company partners with several leading pharmaceutical companies including Daiichi Sankyo, Bayer Pharma and Mitsubishi Tanabe Pharma for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.

BioInvent International AB (BINV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioInvent International AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioInvent International AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BioInvent International AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
BioInvent and Transgene Enter into Co-Development Agreement 11
BioInvent International Enters into Agreement with Alligator Bioscience 12
BioInvent Partners With US Biotech Company 13
BioInvent Enters into Research Agreement with University of Southampton 14
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 15
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 16
Licensing Agreements 17
Pfizer Enters into Licensing Agreement with BioInvent International 17
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 18
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 19
Equity Offering 20
BioInvent International Raises USD10.4 Million in Private Placement of Shares 20
BioInvent Raises USD19.2 Million in Rights Offering of Shares 22
BioInvent Raises USD5.1 Million in Private Placement of Shares 23
Bioinvent Raises USD9.4 Million in Right Issue of Shares 25
BioInvent Completes Rights Offering of Shares for USD7.4 Million 26
BioInvent Completes Private Placement of Shares for USD2.3 Million 27
BioInvent International Completes Rights Offering Of Common Stock For US$3.6 Million 28
BioInvent Raises USD15.5 Million in Rights Offering of Shares 29
BioInvent International AB – Key Competitors 30
BioInvent International AB – Key Employees 31
BioInvent International AB – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Jan 30, 2018: BioInvent Reports Net Sales Of SEK 45 Million In 2017 33
Jul 26, 2017: BioInvent Interim Report 1 January – 30 June 2017 34
May 17, 2017: BioInvent Interim Report 38
Corporate Communications 41
Apr 12, 2018: BioInvent recruits Martin Welschof as new CEO 41
Oct 24, 2017: The CEO of BioInvent Michael Oredsson will resign at the end of the year 42
Product News 43
Oct 16, 2018: BioInvent to Expand Pipeline With New Development Programs in Solid Cancer 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
BioInvent International AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioInvent International AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioInvent International AB, Deals By Therapy Area, 2012 to YTD 2018 8
BioInvent International AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BioInvent and Transgene Enter into Co-Development Agreement 11
BioInvent International Enters into Agreement with Alligator Bioscience 12
BioInvent Partners With US Biotech Company 13
BioInvent Enters into Research Agreement with University of Southampton 14
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 15
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 16
Pfizer Enters into Licensing Agreement with BioInvent International 17
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 18
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 19
BioInvent International Raises USD10.4 Million in Private Placement of Shares 20
BioInvent Raises USD19.2 Million in Rights Offering of Shares 22
BioInvent Raises USD5.1 Million in Private Placement of Shares 23
Bioinvent Raises USD9.4 Million in Right Issue of Shares 25
BioInvent Completes Rights Offering of Shares for USD7.4 Million 26
BioInvent Completes Private Placement of Shares for USD2.3 Million 27
BioInvent International Completes Rights Offering Of Common Stock For US$3.6 Million 28
BioInvent Raises USD15.5 Million in Rights Offering of Shares 29
BioInvent International AB, Key Competitors 30
BioInvent International AB, Key Employees 31
BioInvent International AB, Subsidiaries 32

List of Figures
BioInvent International AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioInvent International AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[BioInvent International AB (BINV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UNITIKA LTD.:企業の戦略・SWOT・財務情報
    UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report Summary UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報
    Summary Kangmei Pharmaceutical Co Ltd (Kangmei) is a manufacturer and distributor of herbal medicine. The company provides herbal raw materials and preparations. Kangmei products include Chinese herbal medicine, bottled single product, hong mei life, xinkaihe senate, chinese medicine derived, medici …
  • VAALCO Energy Inc (EGY):企業の財務・戦略的SWOT分析
    VAALCO Energy Inc (EGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Energy Development Corp (EDC):電力:M&Aディール及び事業提携情報
    Summary Energy Development Corp (EDC), formerly Philippine National Oil Company, is a diversified renewable energy company. The company explores, develops, operates and utilizes geothermal energy and other indigenous renewable energy projects in the Philippines. EDC by utilizing geothermal energy an …
  • QuadGraphics Inc (QUAD):企業の財務・戦略的SWOT分析
    QuadGraphics Inc (QUAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hyundai Steel Co:企業の戦略・SWOT・財務情報
    Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819, a non-systemic yeast recombinant …
  • China Railway Group Ltd:企業の戦略・SWOT・財務情報
    China Railway Group Ltd - Strategy, SWOT and Corporate Finance Report Summary China Railway Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Spotlight Innovation Inc (STLT):企業の財務・戦略的SWOT分析
    Summary Spotlight Innovation Inc (Spotlight Innovation), formerly American Exploration Corp is a developer of proprietary technologies designed to treat rare, emerging and neglected diseases. The company’s product pipeline includes drug candidates for the treatment of cancer derived from specialized …
  • AxoGen Inc (AXGN):企業の財務・戦略的SWOT分析
    Summary AxoGen Inc (AxoGen), formerly LecTec Corp is a provider of surgical solutions to measure and monitor nerve functions. The company offers products such as AxoTouch two-point discriminator, AxoGuard nerve connector, Avance nerve graft, AcroVal NSTMS and AxoGuard nerve protector products, among …
  • Elia System Operator SA (ELI):電力:M&Aディール及び事業提携情報
    Summary Elia System Operator SA (Elia) is a transmission system operator. It owns and operates high-voltage electricity transmission systems in Belgium and Germany. The company transmits electricity from generators to distribution system operators and industrial consumers. Elia also imports and expo …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …
  • Recipharm AB (RECI B):医療機器:M&Aディール及び事業提携情報
    Summary Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The organization's manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, soli …
  • The McClatchy Company (MNI):企業の財務・戦略的SWOT分析
    The McClatchy Company (MNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Avaya Inc.:戦略・SWOT・企業財務分析
    Avaya Inc. - Strategy, SWOT and Corporate Finance Report Summary Avaya Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Cerner Corp (CERN):医療機器:M&Aディール及び事業提携情報
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Tyler Technologies Inc (TYL):企業の財務・戦略的SWOT分析
    Tyler Technologies Inc (TYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Translational Drug Development LLC-製薬・医療分野:企業M&A・提携分析
    Summary Translational Drug Development LLC (TD2) is a drug development organization offers oncology treatments to cancer patients. The organization offers services which include regulatory affairs services, preclinical services, clinical services, and others. It also offers in vivo services, isogeni …
  • Bioactive Bone Substitutes Plc (BONEH):企業の製品パイプライン分析
    Summary Bioactive Bone Substitutes Plc (BBS) is a health technology company that manufactures biologically active medical device implants for orthopedic surgery. The company provides technology platforms, artebone, research and development, patents, and others. It offers artebone which is made up of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆